Sign in
CRSP Stock Price, Chart, Stats & News
CRISPR Therapeutics AG
Save
5.20B
Market cap
–
Current P/E
23.36x
Forward P/E
CRSP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -8560.01% |
Operating margin | -25384.68% |
Pretax margin | -22076.59% |
Net margin | -22215.39% |
Effective tax rate | -0.63% |
ROA | -25.67% |
ROE | -31.53% |
D/E | 0.21x |
Interest coverage ratio | – |
CRSP valuation
P/E | – |
P/S | 1677.36x |
P/B | 2.14x |
P/CF | -11.92x |
P/FCF | -12.69x |
P/OCF | -11.92x |
PEG | 0.43x |
EV multiple | -7.03x |
About
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions.
Similar securities
Based on sector and market capitalization
Report issue